People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Other, Biotechnology, Agriculture, Pharmaceuticals, Other Energy
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Freenome Holdings, Inc. | — | Other | Series D+ | $750.6M | $3.4B | 2019 |
| Syros Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $296.1M | $2.6B | 2018 |
| Fate Therapeutics Inc | — | Biotechnology | Series C | $241.3M | $2.0B | 2009 |
| AgBiome, LLC | — | Agriculture | Series D+ | $216.7M | $1.2B | 2015 |
| Morphic Holding, Inc. | — | Biotechnology | Series C | $200.6M | $1.5B | 2018 |
| Camp4 Therapeutics Corp | — | Biotechnology | Series D+ | $179.6M | $2.2B | 2018 |
| Metacrine, Inc. | — | Pharmaceuticals | Series C | $124.8M | $2.3B | 2015 |
| Promedior Inc | — | Pharmaceuticals | Series B | $46.3M | $739.9M | 2009 |
| Avila Therapeutics Inc | — | Biotechnology | Series B | $45.0M | $893.0M | 2009 |
| Scholar Rock LLC | — | Biotechnology | Series B | $36.3M | $1.4B | 2015 |
| Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.) | — | Pharmaceuticals | Series A | $30.5M | $334.7M | 2012 |
| Sofregen Medical Inc. | — | Biotechnology | Series A | $17.8M | $293.0M | 2016 |
| Sun Catalytix Corp | — | Other Energy | Series A | $13.6M | $42.3M | 2010 |
| Pervasis Therapeutics Inc | — | Biotechnology | Series A | $10.0M | $361.6M | 2009 |
Amir Nashat at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Amir Nashat on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kristina Burow | 4 | 16 |
| Robert Nelsen | 3 | 22 |
| Vicki Sato | 2 | 6 |
| PAUL Grayson | 2 | 5 |
| Jorge Conde | 2 | 4 |
| William Rastetter | 2 | 4 |
| Katrine Bosley | 2 | 4 |
| Timothy Springer | 2 | 3 |
| Bryan Roberts | 1 | 18 |
| Michael Lee | 1 | 15 |
| Kevin Bitterman | 1 | 15 |
| Robert S Langer | 1 | 14 |
| Bruce Booth | 1 | 12 |
| Srinivas Akkaraju | 1 | 10 |
| Michael Higgins | 1 | 9 |
| Vijay Pande | 1 | 9 |
| Carl Weissman | 1 | 8 |
| Peter Kolchinsky | 1 | 8 |
| Robert Epstein | 1 | 8 |
| Robert Metcalfe | 1 | 8 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.